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The nonstructural immediate-early protein pp89 of murine cytomegalovirus (MCMV) is the first viral
protein synthesized after infection and has a regulatory function in viral gene expression. Despite its
localization in the nucleus of infected cells, pp89 is also the dominant antigen recognized by MCMV-specific
cytolytic T lymphocytes. The recombinant vaccinia virus MCMV-iel-VAC, which expresses pp89, was used to
study the capacity of this protein to induce protective immunity in BALB/c mice. Vaccination with
MCMV-iel-VAC induced a long-lasting immunity that protected mice against challenge with a lethal dose of
MCMV but did not prevent infection and morbidity. In vivo depletion of CD8+ T lymphocytes before challenge
completely abrogated the protective immunity. CD8+ T lymphocytes derived from MCMV-iel-VAC-primed
donors and adoptively transferred into sublethally irradiated and MCMV-infected recipients were found to
limit viral replication in host tissues, whereas CD4+ T lymphocytes and pp89-specific antiserum had no
protective effect. The data demonstrate for the first time that a single nonstructural viral protein can confer
protection against a lethal cytolytic infection and that this immunity is entirely mediated by the CD8+
subpopulation of T lymphocytes.
Cytomegaloviruses (CMVs) are members of the beta-
herpes subfamily of the herpesvirus group. In the immuno-
competent host, CMV infection is effectively controlled and
the virus persists in a latent stage. In the immunocompro-
mised host, however, CMV infection represents a major
viral cause of morbidity and mortality (22-24). The analysis
of the immune mechanisms operative in the immunocompe-
tent host is a prerequisite to develop specifically designed
vaccines. Cellular immunity is involved in the control of
CMV infection. It has been suggested that cytolytic T
lymphocytes (CTLs) play a pivotal role, since the ability to
mount a specific CTL response is inversely correlated with
lethal disease, whereas no correlation has been found be-
tween remission ofCMV disease and CMV-specific antibody
titers (22, 27).
The infection of mice with the murine CMV (MCMV)
serves as a general model for CMV infection. We study the
protective function of T lymphocytes and characterize the
viral antigens recognized. Using an adoptive-transfer model,
we have determined that specifically sensitized T lympho-
cytes that contain the CD8 (Lyt-2)-positive subset limit viral
spread, prevent tissue destruction by the virus, and protect
against lethal disease (28, 32-34). Sensitized CTLs detect
both structural and nonstructural viral antigens, and CTLs
with specificity for nonstructural antigens expressed during
the immediate-early (IE) phase ofMCMV replication are the
dominant subset (30, 31). Within the 235-kilobase-pair dou-
ble-stranded linear DNA of the MCMV genome (8), abun-
dant IE transcription originates from three transcription
units, iel, ie2, and ie3, located in a region of about 12
kilobase pairs (12, 13). Transcription unit iel, which is under
the control of a long and complex enhancer element (7), is
predominantly transcribed, and antigens expressed by iel in
transfected cells are detected by IE-specific CTLs (18, 20).
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Several differently spliced mRNAs are transcribed from iel
(13). A 2.75-kilobase mRNA transcribed from gene ieI
contained in transcription unit iel is translated into a non-
structural regulatory phosphoprotein of 89,000 daltons (Da),
the major MCMV IE protein pp89 (13-15, 19).
Several different vaccinia recombinant viruses expressing
single foreign structural viral antigens have been used as
experimental vaccines in a variety of models (for a review,
see reference 21). To selectively analyze the role of a
nonstructural herpesvirus protein in the induction of protec-
tive immunity, we have constructed a recombinant vaccinia
virus containing gene ieI of MCMV (42). Infection of cells
with the vaccinia recombinant virus leads to expression of
the membrane antigen recognized by the IE-specific CTL
clone IEl, and infection of mice with the recombinant virus
induces pp89-specific CTLs in vivo (42). Here we studied the
potential protective effect of the recombinant vaccinia virus
when used as an experimental vaccine. We provide the first
evidence that immunization against a single nonstructural
herpesvirus protein can protect against a lethal course of
infection.
MATERIALS AND METHODS
Mice. Six- to eight-week-old BALB/c mice were bred in
our colony under specific-pathogen-free conditions.
Viruses. The Smith strain of MCMV (VR-194; American
Type Culture Collection, Rockville, Md.) was used as tissue-
cultured virus that was propagated in BALB/c mouse em-
bryo fibroblasts (MEFs) and purified as described previously
(29). For challenge infection of immunized mice, MCMV
salivary gland virus, isolated after three in vivo passages of
MCMV in 3-week-old BALB/c mice, was prepared as a 10%
(wt/vol) homogenate of salivary gland tissue in minimal
essential medium. The virus stock contained 107 PFU of
MCMV per ml. The construction of the vaccinia recombi-
nant virus containing gene ieI of MCMV (MCMV-ieI-VAC)
has been described previously (42).
Viral sensitization and challenge. Mice were sensitized by
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intravenous (i.v.) injection of 2 x 107 PFU of MCMV-iel-
VAC or wild-type vaccinia virus. Sensitization with MCMV
was done by injection of 2 x 105 PFU of tissue-culture-
grown virus into one hind footpad. To test protective immu-
nity after vaccination, mice were challenged by intraperito-
neal (i.p.) application of the indicated doses of MCMV
salivary gland virus (1 50% lethal dose [LD50] equals 105
PFU) (4), and morbidity and mortality were monitored daily
for 30 days.
Adoptive T-lymphocyte transfer. To assess the antiviral
efficacy of T lymphocytes, adoptive-transfer experiments
were performed essentially as described previously (34).
Two hours before cell transfer, recipient mice were sub-
jected to total-body -y irradiation with 6 Gy and infected in
one hind footpad with 2 x 105 PFU of tissue-culture-grown
MCMV. Donor T lymphocytes were enriched to a purity of
more than 95% by passage through nylon-wool columns.
Depletion of the CD8+ and CD4+ subsets was achieved by
incubation with monoclonal antibodies anti-Lyt-2 (hy-
bridoma YTS-169.4, rat immunoglobulin G2b) (5) and anti-
L3T4 (hybridoma GK1.5, rat immunoglobulin G2b) (6),
respectively, followed by complement treatment (34).
In vivo depletion of the CD8+ T-lymphocyte subset. On the
day of challenge with the salivary gland isolate of MCMV,
0.8 mg of monoclonal antibody 169.4 (anti-Lyt-2) (5) con-
tained in 2 mg of protein of partially purified ascites was
injected i.v. into vaccinated mice. The efficacy of depletion
was repeatedly monitored by cytofluorometric analysis, and
the reduction of CD8+ T lymphocytes in spleen and lymph
nodes was always found to be at least 99% (data not shown).
Determination of virus titers in tissue. Titers of infectious
MCMV in the spleen were determined 14 days postinfection
by a plaque assay as described previously (34). Virus titers (x
and y) were regarded as significantly different for P (x versus
y) < a = 0.05 (one sided), where P is the observed
probability value and ot is the selected significance level
(Wilcoxon-Mann-Whitney exact rank sum test).
Detection of virus-specific antibodies. MCMV-specific anti-
bodies were determined by enzyme-linked immunosorbent
assay (ELISA), radioimmunoprecipitation, and virus neu-
tralization.
(i) ELISA. Flat-bottom microdilution plates were coated
with antigen from MCMV-infected MEFs. Infection of
MEFs was performed with a multiplicity of 20 PFU per cell
for 24 h. In the late phase ofMCMV replication, MEFs were
harvested by trypsinization, washed three times in phos-
phate-buffered saline (PBS), and lysed by ultrasonication. A
0.1-ml portion of cell lysate (equivalent to 105 cells) was
added to each well, and adsorption was allowed for 12 h at
4°C. The excess binding sites were saturated with 1% bovine
serum albumin in PBS. The plates were then washed in PBS,
and 0.1-ml portions of serum dilutions were added to indi-
vidual wells. After 2 h of incubation at room temperature,
the plates were washed with PBS-0.05% Tween 20, 0.1 ml of
a 1:2,000 dilution of horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin G (heavy and light chains) anti-
body (TAGO, Burlingame, Calif.) was added to each well,
and the plates were kept at room temperature for a further 1
h. After the plates were washed, development with the
substrate o-phenylenediamine (Sigma Chemical Co., St.
Louis, Mo.) was allowed for 20 min at room temperature.
The reaction was stopped with 2 M sulfuric acid, and the
optical density at 492 nm was measured in an ELISA
microplate reader.
(ii) Radioimmunoprecipitation. Labeling of cells with [35S]_
methionine, preparation of cell lysates, and immunoprecip-
itation were carried out as described previously (15).
(iii) Virus neutralization. The titer of MCMV-specific
neutralizing antibodies was determined by the plaque reduc-
tion assay on MEF monolayers grown in 48-well flat-bottom
plates. Sera were serially diluted, and 200 ,ul of each dilution
was mixed with 25 ,ul of rabbit complement and ca. 100 PFU
of MCMV contained in 25 RIl of medium. The mixture was
incubated at 37°C for 1 h before performance of the plaque
assay as described previously (34). Control sera positive or
negative for antibody to MCMV were included. The titer
indicates the serum dilution resulting in 50% reduction of
plaque numbers.
RESULTS
CD8+ T lymphocytes sensitized by the nonstructural IE
protein pp89 limit MCMV multiplication in host tissue. Pre-
vious studies have established that T lymphocytes of the
CD8+ subset sensitized in donor mice during infection with
MCMV limit virus multiplication in various tissues of in-
fected, immunocompromised recipient mice after adoptive
lymphocyte transfer (28, 32, 34). Furthermore, evidence was
provided that this antiviral effect, protection against viral
interstitial pneumonia, and survival from MCMV disease
can be mediated by a function of CD8+ T lymphocytes
specific for IE antigens (33). However, it was unknown
whether a protective antiviral immune response can be
induced by the nonstructural phosphoprotein pp89 encoded
by gene iel, by another IE protein encoded by the IE
transcription unit ie2 or ie3, or by any other product of a
differently spliced transcript derived from transcription unit
iel. A role for pp89 in protective immunity could be docu-
mented by sensitization of adoptive-transfer donors with the
recombinant virus MCMV-ieI-VAC, which contains the
intron-free continuous open reading frame of ieI and ex-
presses pp89 exclusively (Fig. 1). This result was not at all
clear a priori since the detection of pp89-specific CTL
activity after priming with MCMV-ieI-VAC required an in
vitro period of restimulation with MCMV (42).
For the relevant negative control, nylon-wool-purified T
lymphocytes derived after priming with wild-type vaccinia
virus were transferred (Fig. 1, column A). These cells were
not able to control MCMV replication in the spleen of
immunocompromised adoptive-transfer recipients, and the
virus titer was not different from those observed after no
transfer of cells or after transfer of nonprimed T lympho-
cytes (data not shown). As expected based on a previous
study (28), T lymphocytes derived from donors that were
latently infected with MCMV effectively limited the spread
of MCMV in the spleen (Fig. 1, column B). Potentially, in
addition to detecting IE antigens as dominant antigens, the
antiviral effector cells in this group could be specific for a
multitude of other viral nonstructural as well as structural
proteins. Compared with the results for the vaccinia virus
control, T lymphocytes sensitized against pp89 expressed by
MCMV-ieI-VAC significantly limited MCMV multiplication
(Fig. 1, compare columns A and C, P = 0.005). This antiviral
function resided within the CD8+ subset of MCMV-ieI-
VAC-primed T lymphocytes (Fig. 1, column D); MCMV-ieI-
VAC-primed CD4+ T lymphocytes did not exert an antiviral
effect (Fig. 1, column E).
The different efficacy of T lymphocytes sensitized with
whole MCMV and with MCMV-ieI-VAC (Fig. 1, compare
columns B and C) is not surprising since infection with
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FIG. 1. In vivo antiviral function of MCMV-iel-VAC-primed T
lymphocytes. The in vivo antiviral efficacy of sensitized T lympho-
cytes was tested by adoptive lymphocyte transfer. Throughout the
experiment, 2 x 105 nylon-wool-purified T lymphocytes derived
from spleens and lymph nodes of immunized mice were transferred
i.v. into irradiated, infected recipient mice. Virus titers in the
spleens of the recipients were determined at day 14 postinfection.
Individual titers are signified by closed circles, and median values
are indicated by horizontal lines. The broken line represents the
detection level, which was 50 PFU of MCMV. Columns: A, T
lymphocytes derived from mice immunized i.v. with 2 x 107 PFU of
wild-type vaccinia virus (VAC) 21 days earlier; B, T lymphocytes
derived from latently infected mice 4 months after intraplantar
infection with 2 x 105 PFU of MCMV; C, T lymphocytes derived
from mice immunized i.v. with 2 x 107 PFU of MCMV-iel-VAC
recombinant virus 21 days earlier; D, T lymphocytes of group C
depleted of the CD4+ subset; E, T lymphocytes of group C depleted
of the CD8+ subset.
vaccinia virus generates a strong vaccinia virus-specific
T-lymphocyte response that can be demonstrated directly
without in vitro restimulation (17), whereas only a minor
fraction of the sensitized T lymphocytes is directed against
the insert gene product and can be disclosed only upon in
vitro selection by restimulation with the parent virus of the
insert (42).
The data positively document for the first time that CD8+
T lymphocytes sensitized by a single nonstructural, regula-
tory protein of MCMV, the IE protein pp89, limit virus
multiplication in host tissue.
MCMV-iel-VAC protects mice against challenge infection
with a lethal dose of MCMV. When testing a single viral gene
product for its potential use as a vaccine, it is a conditio sine
qua non to prove that immunity elicited by the candidate
protein is sufficient for protection. We therefore compared
the protective potential of vaccination with MCMV-iel-VAC
with that of vaccination with a nonlethal dose of MCMV
(Fig. 2). Three weeks after vaccination, a challenge infection
was initiated by i.p. application of 5 LD50s of the highly
virulent salivary gland isolate of MCMV (11, 25). Nonimmu-
nized mice and those immunized with wild-type vaccinia
virus died of acute MCMV disease within 6 to 8 days
postchallenge. After vaccination with the infectious, tissue-
culture-attenuated isolate of MCMV all mice survived (Fig.
CD8+
CD8-








FIG. 2. Protection against challenge infection. Groups of 6 to 10
mice were immunized, as indicated in the legend to Fig. 1, 21 days
before an i.p. challenge infection with 5 LD50s of the salivary gland
isolate of MCMV. (Left panel) No immunization (---- ), vaccina-
tion with MCMV (U), or vaccination with MCMV and in vivo
depletion of CD8+ T lymphocytes on the day of the challenge (l).
(Right panel) Immunization with wild-type vaccinia virus (----),
vaccination with MCMV-ieI-VAC (0), or vaccination with MCMV-
iel-VAC and in vivo depletion of CD8+ T lymphocytes on the day of
the challenge (0).
2, left panel). The protection was still effective when on the
day of challenge infection, CD8+ T lymphocytes were de-
pleted in vivo by infusion of antibodies against the CD8
antigen, indicating that protection was not, or at least not
only, mediated by antiviral T lymphocytes of the CD8+
subset. Vaccination with MCMV-ieI-VAC also provided
protection (Fig. 2, right panel), but this protection was
completely dependent upon the presence of CD8+ T lym-
phocytes. It should be noted that in four experiments the
survival rate of mice immunized with MCMV-ieI-VAC var-
ied between 50 and 100%, with an average of 71%. Vacci-
nation with MCMV-ieI-VAC did not prevent infection and
morbidity: all individuals developed lethargy, hunching, and
a wasting syndrome, as did nonimmunized mice. By day 7
postchallenge, however, MCMV-iel-VAC-primed mice were
recovering, whereas the nonimmune controls all died of
MCMV disease. In essence, pp89 induced a protective
immunity mediated by CD8+ T lymphocytes that protected
against a lethal course of disease.
Vaccination with whole MCMV induces protective antibod-
ies. It became apparent from the vaccination-challenge ex-
periments that protection by MCMV-ieI-VAC is entirely
based on CD8+ T lymphocytes, whereas vaccination with
TABLE 1. Antibody response to MCMV and MCMV-ieI-VAC
Protective
ELISA Immuno- Neutrali- ProectbSensitization tIterI precipitation of zation of effect(MCMV proteins virus (survivorsttotal)
MCMV 512 89-kDa and 40 6/6
several others
MCMV-iel-VAC 512 89-kDa <2 0/7
Vaccinia virus <2 None <2 0/7
"Reciprocal of serum dilution giving half-maximum activity.
"Mice were passively immunized with 0.5 ml of pooled serum samples from
five mice immunized 3 to 4 weeks earlier and were challenged 2 h later with 5
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MCMV induces an additional protective mechanism (Fig. 2).
We therefore analyzed and compared the antibody re-
sponses after immunization with MCMV and MCMV-ieI-
VAC (Table 1).
Sera were assayed by ELISA, immunoprecipitation, and
neutralization in vitro. Serum samples from both MCMV-
infected mice and mice primed with MCMV-ieI-VAC had
comparable antibody titers in the ELISA. They differed,
however, when the ability to precipitate MCMV proteins
was tested. MCMV immune serum immunoprecipitated sev-
eral polypeptides from MCMV-infected MEFs, including an
89-kDa protein, whereas serum from MCMV-ieI-VAC-
primed mice precipitated only an 89-kDa protein indistin-
guishable from pp89 (15). A neutralizing antibody titer was
detected in MCMV immune serum whereas no neutralizing
activity was present in sera from MCMV-ieI-VAC- or wild-
type vaccinia virus-primed mice. Absence of neutralization
in vitro, however, does not exclude protective effects of
antiserum in vivo where infected cells with surface-bound
antibodies could be eliminated by cellular mechanisms.
Thus, to determine whether antibodies induced by MCMV
or MCMV-ieI-VAC protect mice against challenge infection,
mice were passively immunized by serum transfer (Table 1).
All mice that received MCMV immune serum survived the
challenge, whereas mice that received sera from MCMV-iel-
VAC- or wild-type vaccinia virus-primed mice died within 7
days. This demonstrated that pp89-specific antibodies gen-
erated after infection with MCMV-iel-VAC neither neutral-
ize MCMV in vitro nor protect against lethal MCMV chal-
lenge in vivo and, on the other hand, strongly suggested that
antibodies specific for other viral proteins contributed to the
protection seen after vaccination with MCMV. It must be
noted, however, that there is no correlation between serum
antibody titers and the capacity to clear virus from infected
tissues (33).
Longevity of protection induced by MCMV-iel-VAC. Evi-
dence presented so far demonstrates that protection by the
experimental vaccine was solely based upon the generation
of a cellular immune response, with T lymphocytes of the
CD8+ phenotype representing the antiviral effector cells.
This mode of protection is different from the protective
principle of vaccines presently used, which depend upon the
induction of a long-lasting neutralizing antibody response. It
was therefore important to test whether MCMV-ieI-VAC
could induce a lasting protective immunity. To address this
question, mice from the batch characterized by the data
shown in Fig. 2 were challenged with a lethal dose of the
salivary gland isolate of MCMV at 4 months after vaccina-
tion. The results (Table 2) document the enduring protective
effect of the experimental vaccine.
DISCUSSION
We tested the protective effect of a recombinant vaccinia
virus expressing the nonstructural regulatory IE protein
TABLE 2. Long-lasting protective immunity after
vaccination with MCMV-ieI-VAC"
Sensitization Survivors (tl = 6)
MCMV-ieI-VAC........... 6




a Four months after vaccination, mice were challenged i.p. with 2.5 LD,(,s
of the salivary gland isolate of MCMV.
pp89 of MCMV and report three findings: (i) vaccination
protected the animals against mortality but not against
infection and morbidity after challenge with a lethal dose of
MCMV, (ii) the protective effect was long lasting, and (iii)
protection was a function of specifically sensitized CD8+ T
lymphocytes.
In cellular immunity to alphaherpesviruses, glycoproteins
have been considered the primary candidates to induce a
CTL response. Evidence for recognition of gB (48; H.
Openshaw, personal communication), gC (35), and gD (48,
49) of herpes simplex virus by specific murine or human
CTLs has been presented. The protective role of herpesvi-
rus-glycoprotein-specific CTLs during herpesvirus infection
in vivo is not yet clear however, although a protective effect
of gD-specific T lymphocytes has been shown (44). Because
we also detected CTLs with specificity for structural pro-
teins (30, 31), the recognition of MCMV glycoproteins by a
minority of CTLs is quite likely.
For several viruses, it has been documented that CTLs
recognize viral proteins that are not transported to the
plasma membrane to exert their specific function in viral
replication. This includes structural (2, 3, 9, 10, 40, 43, 46,
47) and nonstructural (3, 31, 38) viral proteins. The mode of
membrane presentation of these proteins as antigens for
CTL recognition is unknown. The finding that short peptides
containing the relevant epitope can render cells susceptible
for lysis by CTLs suggests that antigen presentation involves
intracellular fragmentation of the polypeptide (39, 41).
Although viral proteins which are located inside the in-
fected cell have been reported to represent target antigens
for CTLs, few reports have directly addressed the question
of whether these proteins could induce a protective immune
response. In an early report, the protective activity of the
simian virus 40 nonstructural T antigen against tumor for-
mation was described (38). After vaccination with vaccinia
virus recombinants expressing the nucleocapsid protein of
respiratory syncytial virus and influenza virus, virus titer
reduction was observed after respiratory syncytial virus
challenge (16) and a certain degree of protection against
mortality was observed after influenza A virus challenge (1),
respectively. Similar results were obtained when the purified
nucleoprotein of influenza A virus was used for immuniza-
tion (45) and when CTL clones specific for the nucleoprotein
were adoptively transferred (37).
In the present report, we show for the first time that
structural viral proteins are not required for the induction of
protective immunity against a lethal challenge with a cyto-
lytic virus. The results, which are also supported by data
published previously (28, 32-34), provide definite evidence
that T lymphocytes with specificity for a single IE antigen of
MCMV, the phosphoprotein pp89, control virus multiplica-
tion and can protect against lethal disease. The effector cells
have the CD8+ phenotype. The finding that pp89-specific
antibodies induced by MCMV-ieI-VAC had neither neutral-
izing activity in vitro nor protected in vivo demonstrated that
these antibodies did not contribute to the protection ob-
served with MCMV-ieI-VAC. Because the antigen detected
by the effector cells is expressed only after cell infection and
initiation of viral gene expression, the pp89-specific CD8+ T
lymphocytes cannot prevent cell infection and therefore
after challenge of mice with a high dose of virus, do not
prevent morbidity. They do, however, prevent mortality and
aid recovery. A more effective recombinant-virus vaccine
could perhaps be achieved if, in addition to the antigen
required for the generation of protective CTLs, an antigen is
expressed that gives rise to a neutralizing antibody response.
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There is a demand for vaccines that reduce the incidence
of CMV-associated disease. Vaccines based on inactivated
CMV have some protective effect (24, 26) but cannot induce
CTLs against nonstructural proteins. On the other hand,
attenuated live CMV vaccines do express the IE proteins but
include the risk of viral latency and reactivation to produc-
tive cytolytic infection. The experimental vaccine described
here has the advantage of inducing CTLs without any risk of
establishing viral latency. Considering the central role of
major histocompatibility complex glycoproteins in the pre-
sentation of antigens for recognition by T lymphocytes, it
may appear premature to extrapolate from experimental
studies in a selected mouse inbred strain to the situation in
humans. Since, however, the CTL response to the ieI gene
product was surprisingly dominant and because the structure
and regulation of the MCMV iel gene (14) closely resemble
those of the IEl gene of human CMV (HCMV) (36), we have
predicted that the HCMV IEl gene product should represent
a major CTL antigen in HCMV infection (18). The finding
that the isolated HCMV IE1 product is detected by human
CTLs and indeed represents a major CTL antigen (J. G. P.
Sissons and L. K. Borysiewicz, personal communication)
confirms this prediction and justifies the use of MCMV
infection as a model for human CMV disease.
Although the protective effect of CD8+ T lymphocytes is
long lasting in immunocompetent hosts, it is evident that this
kind of vaccination protocol will not provide protection
against CMV infection when CD8+ T lymphocytes are lost
during induced or acquired immunodeficiency later on. Ex-
periments with the murine model indicate possible alterna-
tives. Specifically sensitized CD8+ T lymphocytes can be
induced during the immunocompetent state, collected, and
stored. Autologous cells or cells from major histocompati-
bility complex-compatible donors could then be adoptively
transferred during the immunodepressed state. Since for
some clinical situations the incidence of CMV infection is
known and because studies of the cytoimmunotherapy of
murine CMV disease have shown that CD8+ T lymphocytes
can be used also for postexposure therapy (28, 32, 34), in
theory there should be no principal obstacle to specific
cytoimmunotherapy of human CMV disease.
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